Acadia Pharmaceuticals (ACAD) EBITDA Margin (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly EBITDA Margin of 1.72% for Q1 2026, down 962.0% year-over-year from 0.2% in Q1 2025, and down 128.12% quarter-over-quarter from 6.12% in Q4 2025.
Acadia Pharmaceuticals (ACAD) EBITDA Margin (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' EBITDA Margin history runs 17 years deep, the most recent figure standing at 1.72% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 962.0% year-over-year to 1.72%; the TTM figure through Mar 2026 stood at 7.39% (down 1619.0% YoY), while the FY2025 annual figure was 9.78%, down 1431.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 1.72%, down from 6.12% in the prior quarter.
- The five-year high for EBITDA Margin was 59.13% in Q4 2024, with the low at 97.88% in Q1 2022.
- The 5-year median for EBITDA Margin is 6.12% (2025), against an average of 6.28%.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin surged 5264 bps in 2023, then sank 5301 bps in 2025.
- Acadia Pharmaceuticals' EBITDA Margin stood at 33.75% in 2022, then jumped by 145 bps to 15.12% in 2023, then surged by 291 bps to 59.13% in 2024, then sank by 90 bps to 6.12% in 2025, then sank by 128 bps to 1.72% in 2026.
- Business Quant data shows ACAD's EBITDA Margin at 1.72% in Q1 2026, 6.12% in Q4 2025, and 12.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 12.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.29% |
| Mar 31, 2026 | -1.72% |
| Dec 31, 2025 | 6.12% |
| Sep 30, 2025 | 12.83% |
| Jun 30, 2025 | 12.24% |
| Mar 31, 2025 | 7.90% |
| Dec 31, 2024 | 59.13% |
| Sep 30, 2024 | 12.64% |
| Jun 30, 2024 | 12.58% |
| Mar 31, 2024 | 7.39% |
| Dec 31, 2023 | 15.12% |
| Sep 30, 2023 | -27.29% |
| Jun 30, 2023 | 1.84% |
| Mar 31, 2023 | -45.23% |
| Dec 31, 2022 | -33.75% |
| Sep 30, 2022 | -23.61% |
| Jun 30, 2022 | -25.01% |
| Mar 31, 2022 | -97.88% |
| Dec 31, 2021 | -34.15% |
| Sep 30, 2021 | -11.63% |